ResMed 관리
관리 기준 확인 4/4
ResMed CEO는 Mick Farrell, Mar2013 에 임명되었습니다 의 임기는 11.67 년입니다. 총 연간 보상은 $ 14.12M, 8.3% 로 구성됩니다. 8.3% 급여 및 91.7% 보너스(회사 주식 및 옵션 포함). 는 $ 111.01M 가치에 해당하는 회사 주식의 0.31% 직접 소유합니다. 111.01M. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 7 년입니다.
주요 정보
Mick Farrell
최고 경영자
US$14.1m
총 보상
| CEO 급여 비율 | 8.3% |
| CEO 임기 | 11.7yrs |
| CEO 소유권 | 0.3% |
| 경영진 평균 재임 기간 | 2.8yrs |
| 이사회 평균 재임 기간 | 7yrs |
최근 관리 업데이트
Recent updates
Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why
Nov 13
We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease
Nov 01Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Oct 20ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price
Oct 08Why ResMed's Rally Is Just Getting Started
Sep 18ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors
Sep 13ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53
Aug 05Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?
Jul 29Returns On Capital Are A Standout For ResMed (NYSE:RMD)
Jul 15ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating
Jul 03An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued
Jul 02ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Apr 30Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 30ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear
Apr 18With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case
Mar 22Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future
Mar 10An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued
Feb 12Why ResMed Is One Of My Top Picks In 2024
Jan 22A First Look At ResMed
Jan 09ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk
Dec 20Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital
Dec 06Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now
Nov 10Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?
Nov 01ResMed: Weight-Loss Drug Worries Provide Buying Opportunity
Oct 28ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity
Sep 12ResMed Has Become A Steal (Rating Upgrade)
Aug 10ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 07ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger
Jul 30Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Jul 16Compound Your Wealth With ResMed
Jul 04A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)
Jul 02We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt
May 26CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$1b |
| Jun 30 2024 | US$14m | US$1m | US$1b |
| Mar 31 2024 | n/a | n/a | US$958m |
| Dec 31 2023 | n/a | n/a | US$890m |
| Sep 30 2023 | n/a | n/a | US$907m |
| Jun 30 2023 | US$14m | US$1m | US$898m |
| Mar 31 2023 | n/a | n/a | US$863m |
| Dec 31 2022 | n/a | n/a | US$809m |
| Sep 30 2022 | n/a | n/a | US$786m |
| Jun 30 2022 | US$12m | US$1m | US$779m |
| Mar 31 2022 | n/a | n/a | US$779m |
| Dec 31 2021 | n/a | n/a | US$522m |
| Sep 30 2021 | n/a | n/a | US$500m |
| Jun 30 2021 | US$10m | US$1m | US$475m |
| Mar 31 2021 | n/a | n/a | US$457m |
| Dec 31 2020 | n/a | n/a | US$699m |
| Sep 30 2020 | n/a | n/a | US$680m |
| Jun 30 2020 | US$10m | US$1m | US$622m |
| Mar 31 2020 | n/a | n/a | US$513m |
| Dec 31 2019 | n/a | n/a | US$455m |
| Sep 30 2019 | n/a | n/a | US$419m |
| Jun 30 2019 | US$10m | US$967k | US$405m |
| Mar 31 2019 | n/a | n/a | US$446m |
| Dec 31 2018 | n/a | n/a | US$450m |
| Sep 30 2018 | n/a | n/a | US$335m |
| Jun 30 2018 | US$9m | US$934k | US$316m |
보상 대 시장: Mick 의 총 보상 ($USD 14.12M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 12.73M ).
보상과 수익: Mick 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Mick Farrell (52 yo)
11.7yrs
테뉴어
US$14,120,829
보상
Mr. Michael J. Farrell, also known as Mick, BE, SM, MBA, served as Director of Fullbay, Inc. since May 2023 until 2023. He serves as Member of Advisory Board at Green Sun Medical, LLC. He serves as the Chi...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Chairman | 11.7yrs | US$14.12m | 0.31% $ 111.0m | |
| Founder | no data | US$719.69k | 0.056% $ 20.0m | |
| Chief Financial Officer | 18.8yrs | US$3.23m | 0.065% $ 22.9m | |
| Chief Legal Officer & Secretary | 1.3yrs | US$2.15m | 0.0064% $ 2.3m | |
| Chief Product Officer | 8.5yrs | US$3.60m | 0.013% $ 4.5m | |
| Chief Commercial Officer - SaaS | 2.8yrs | US$3.53m | 0.013% $ 4.7m | |
| Chief Information Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Chief Investor Relations Officer | 1.6yrs | 데이터 없음 | 데이터 없음 | |
| Chief Compliance Officer | 6.8yrs | 데이터 없음 | 데이터 없음 | |
| Chief Marketing Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Chief People Officer | 3.7yrs | 데이터 없음 | 데이터 없음 | |
| Special Advisor | less than a year | US$6.67m | 0% $ 0 |
2.8yrs
평균 재임 기간
57yo
평균 연령
경험이 풍부한 관리: RMD 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Chairman | 11.7yrs | US$14.12m | 0.31% $ 111.0m | |
| Founder | 35.4yrs | US$719.69k | 0.056% $ 20.0m | |
| Independent Director | 19.3yrs | US$348.72k | 0.010% $ 3.6m | |
| Lead Independent Director | 19.8yrs | US$381.22k | 0.014% $ 5.0m | |
| Independent Non-Executive Director | 5.5yrs | US$329.97k | 0.0046% $ 1.6m | |
| Independent Director | 6yrs | US$329.97k | 0.0060% $ 2.1m | |
| Independent Director | 11yrs | US$369.97k | 0.010% $ 3.6m | |
| Independent Director | 7yrs | US$334.97k | 0.0052% $ 1.8m | |
| Independent Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Independent Director | 3yrs | US$329.97k | 0.0014% $ 503.3k | |
| Independent Director | 3yrs | US$329.97k | 0.0014% $ 503.3k |
7.0yrs
평균 재임 기간
60yo
평균 연령
경험이 풍부한 이사회: RMD 의 이사회는 경험(평균 재직 기간 7 년)으로 간주됩니다.